ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Significant Implications Of miR-126 Expression With Respect to Its Target Gene VEGFA in the Pathogenesis of Recurrent Pregnancy Losses (RPL)-a Study in High Incidence Zone.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveOwing to crucial role played by MicroRNA-126 (miR-126) in vascular development and regulation of vascular endothelial growth factor (VEGFA), this study determined the role of miR-126 and its target gene VEGFA in the pathogenesis of recurrent pregnancy loss (RPL) in women against healthy controls.
methodsA total of 40 samples were collected from women who had experienced consecutive RPL at 20 weeks of gestation when compared to healthy controls with full-term successful pregnancies. The relative expression of miR-126 and VEGFA in plasma was quantified using quantitative real-time polymerase chain reaction (qRT-PCR).
resultsmiR-126 expression was significantly up regulated in RPL patients compared to controls (p < 0.0001), with a median fold change of 3.13 (IQR: 1.25–5.78). Conversely, VEGFA mRNA expression was significantly down regulated in RPL patients (p < 0.0001), with a median fold change of 0.29 (IQR: 0.12–0.67). Moreover, no substantial differences were found in relative expression of miR-126 and VEGFA mRNA among categories of various variables in RPL group respectively. Correlation analysis revealed a negative association between miR-126 and VEGFA expression in RPL cases (r = -0.165). In healthy controls, the miR-126 expression was positively correlated with expression levels of VEGFA mRNA with correlation coefficient (r) = 0.925; p < 0.01. However, the correlation between miR-126 and VEGFA mRNA was not statistically significant in the RPL group.
conclusionsOur findings suggest that dysregulation of miR-126 and VEGFA is associated with RPL. These markers may serve as potential diagnostic and prognostic tools for idiopathic RPL. Furthermore, restoring the normal expression of these molecules could represent a novel therapeutic approach for this condition.
Indexed as
Identifiers
41731266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.